A phase II study of re-treatment of myelofibrosis patients with ruxolitinib/Jakavi after treatment interruption due to loss of response and/or adverse event

To evaluate the effect of re-treatment with ruxolitinib on reduction in spleen volume of at least 20% from baseline, by Week 24

primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (PPV MF)and post essential thrombocythemia vera (PETMF)